Ammonia metabolism pathway via phenylacetylglutamine formation (PAGN pathway)

The ammonia metabolism pathway via phenylacetylglutamine formation is a pharmacological nitrogen-scavenging mechanism used to treat hyperammonemia in patients with urea cycle disorders (UCDs) (Source: FDA Label for Ravicti, 2013). This pathway is primarily engaged by drugs such as sodium phenylbutyrate and glycerol phenylbutyrate, which are converted in the body to phenylacetate (Source: Brusilow, S. W., 1991, Pediatric Research). Phenylacetate then undergoes enzymatic conjugation with glutamine to produce phenylacetylglutamine (PAGN), which is subsequently excreted in the urine (Source: Mokhtarani, M., et al., 2012, Molecular Genetics and Metabolism). Because glutamine is a major carrier of waste nitrogen, the removal of PAGN effectively eliminates two nitrogen atoms per molecule, bypassing the defective urea cycle (Source: Lichter-Konecki, U., et al., 2011, GeneReviews). This process helps maintain safe systemic ammonia levels and prevents the neurotoxic effects associated with ammonia accumulation, such as cerebral edema and irreversible brain damage. Clinical management involves monitoring urinary PAGN levels to ensure adequate nitrogen removal and to adjust drug dosing (Source: Mokhtarani, M., et al., 2012).

Other names

Nitrogen scavenging pathwayPhenylbutyrate-phenylacetate-glutamine pathwayAlternative pathway of nitrogen excretionPhenylacetylglutamine (PAGN) formation

Nitrogen scavenging via the conjugation of phenylacetate with glutamine to form phenylacetylglutamine, which is excreted renally, removing two equivalents of nitrogen per molecule.